PulseAugur
EN
LIVE 22:03:14
中文(ZH) 复星医药：拟出资4.14亿元参与肝病创新药公司星曜坤泽B轮融资及股权转让

Fosun Pharma invests 414M yuan in liver disease drug developer Xingyao Kunze

By PulseAugur Editorial · [1 sources] ·

Fosun Pharma is investing 414 million yuan in a Series B funding round for Xingyao Kunze, a company focused on innovative liver disease drugs. This investment, which includes acquiring shares from existing shareholders, will give Fosun Pharma a 20.87% stake in Xingyao Kunze. The move aims to expand Fosun Pharma's pipeline in liver disease treatments. AI

IMPACT Minimal direct impact on AI operators; focuses on pharmaceutical R&D.

RANK_REASON Significant funding round for a company developing innovative drugs. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Fosun Pharma invests 414M yuan in liver disease drug developer Xingyao Kunze

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Significant funding round for a company developing innovative drugs. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
105 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Fosun Pharma: Plans to invest 414 million yuan to participate in the Series B financing and equity transfer of innovative liver disease drug company Star-X Therapeutics

    36氪获悉，复星医药公告，公司控股子公司复星医药产业拟出资共计4.14亿元参与星曜坤泽B轮融资并受让联营公司苏州基金、天津基金所持部分股权。其中，拟出资2.18亿元认缴星曜坤泽293.68万元新增注册资本，拟出资1.97亿元受让苏州基金、天津基金所持合计308.65万元存续注册资本。交易完成后，复星医药产业将持有星曜坤泽20.87%股权。标的公司主要从事肝病创新药物的研究和开发。本次投资构成关联交易，旨在丰富公司在肝病治疗领域的管线布局。

RELATED TOPICS